Dr. B. R. Shetty Research Centre inaugurated

The inauguration ceremony was attended by Mr. M. D. Mallya, Chairman & Managing Director, Bank of Baroda, Mr. V. H. Thatte, General Manager (International) GCC, Bank of Baroda, Mumbai, Mr. K. V. Rama Moorthy – Chief Executive (GCC Operations) Bank of Baroda, Mr. Narendra K. Batra – Deputy General Manager, Abu Dhabi Branch, Bank of Baroda, Dr. Ahmad Zohbi – Managing Director, Amreet Trading, Mr. Sharad Bhandari Managing Director, Ardent Advisory, top officials of Neopharma

Dubai: 11 September 2012

By:  Zulfiqar Shah

Dr. B. R. Shetty – MD & CEO of Neopharma quoted the Hippocratic Oath as his guiding principle, “I will prescribe regimens for the good of my patients according to my ability and my judgments and never do harm to anyone.”

Sharing his vision, Dr. B. R. Shetty said, “The future of healthcare can be assured by providing hi-tech pharmaceutical products and healthcare services to the UAE community and the neighboring regions.”

While dedicating the Dr. B.R. Shetty Research Centre to the community, Dr. B.R. Shetty described the research centre as the cornerstone of innovation in pharmaceutical formulations, new drug delivery systems, nanotechnology and biological products for chronic or life threatening diseases.

Dr. B. R. Shetty described the Research Centre as a pivotal hub for the development of novel drug delivery systems aimed at the treatment of Diabetes mellitus and Cancer. In this attempt neopharma has introduced modified release glyclazide(Glyka MR) & extended release metformin tablets (Neomet XR)for diabetic, Clarithromycin modified release(Resclar MR) tablets in antibiotic segment & Diclofenac sustained release tablets (Neoflam retard).

The research centre has collaborated with the Arkansas University for the development of microfiber nanotechnology for glucose sensors and nanotechnology based microchips for neurodegenerative disorders. In our collaboration with the biotech leader Biocon we have introduced novel nanotech product albumin bound paclitaxel for the treatment of breast cancer.

“Neopharma dedicates this world class facility to medical science.” Dr. Shetty added.Speaking on the occasion, Chief Guest – Mr. M. D. Mallya – Chairman & Managing Director, Bank of Baroda said, “Dr. Shetty has always been an epitome of service to mankind. This research centre is yet another feather in his colourful cap. Neopharma has aptly named it after him. I am sure that human welfare will be the top most priority in the preamble of the research centre. I wish the expert research team, all the very best in each of their endeavours.”

Neopharma is a premier pharmaceutical manufacturing company of UAE, started in 2003. It lays strong emphasis on research towards development of processes and products that are patent non-infringing – a route that can propel the company towards attaining leading position in the Middle East. Neopharma follows global benchmarks in manufacturing technology and efficient control methods. Neopharma employs the latest automated PLC controlled machines, procured from the world’s best manufacturers for the entire manufacturing and development process in compliance with international regulations for pharmaceutical development – ICH Q8 guidelines. To give a wider scope to its vision, Neopharma has partnered with leading multinational companies for the development and manufacturing of new formulations.